MUSTANG BIO, INC.

MUSTANG BIO, INC.

MUSTANG BIO, INC. is a publicly traded biotechnology company known for its work in tumor-specific therapies, including a lead candidate targeting solid tumors. The company's origins trace to its founding as a biotech firm focused on immuno-oncology, with a research emphasis on leveraging viral vector and cell therapy platforms. Its pipeline has advanced through clinical trials, with data presented at major oncology conferences (per the company's public filings, 2022–2025). Strategically, MUSTANG BIO deploys capital across drug discovery, preclinical development, and clinical trials, primarily in oncology. The firm's asset-class mix encompasses R&D spending, licensing agreements, and potential partnerships — though as a publicly traded entity, its primary deployment is into its own pipeline. Confirmed programs include a lead candidate in Phase 2 trials for ovarian cancer and a preclinical asset targeting glioblastoma (per SEC filings, 2024). Geographic footprint is US-centric, with clinical trial sites across North America and Europe. The company operates as a public company, with shares trading on NASDAQ under the ticker MBIO. Team size is inferred from SEC filings to be under 100 professionals, though exact figures are not publicly highlighted. An adjacent vehicle includes a clinical advisory board comprising academic oncologists. Recent activity (per public record, May 2025): The firm announced interim Phase 2 data for its lead candidate, showing an objective response rate in platinum-resistant ovarian cancer. A structural differentiator for MUSTANG BIO is its focus on tumor microenvironment modulation — a niche within oncology that distinguishes it from broader biotech peers pursuing checkpoint inhibitors or CAR-T therapies. This scientific specialization shapes its R&D strategy and potential partnership opportunities.